CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BRII-198Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)

Name (Synonyms) Correlation
drug938 Dutasteride Wiki 1.00
drug2264 Proxalutamide Wiki 1.00
drug1489 Ivermectin Wiki 0.22
drug313 Azithromycin Wiki 0.17
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D011470 Prostatic Hyperplasia NIH 1.00
D006965 Hyperplasia NIH 1.00
D000505 Alopecia NIH 0.71
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0008711 Benign prostatic hyperplasia HPO 1.00
HP:0002293 Alopecia of scalp HPO 0.71

There is one clinical trial.

Clinical Trials

1 A Phase 1 Randomized, Single-blind, Placebo-controlled, Single Ascending Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Human Monoclonal Antibody, BRII-198 Administered Intravenously to Healthy Adult Volunteers

This is a phase 1 study in which healthy adult volunteers will receive BRII-198 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.

NCT04479644 COVID-19 Drug: BRII-198 Drug: Placebo

Primary Outcomes

Measure: Incidence of adverse events (AEs) by CTCAE v5.0

Time: up to 24 weeks

Measure: Proportion of subjects with SAEs

Time: up to 24 weeks

Measure: Proportion of subjects with infusion-related reactions

Time: up to 24 weeks

Measure: Proportion of subjects with hypersensitivity reactions

Time: up to 24 weeks

Secondary Outcomes

Measure: Serum Concentration of BRII-198

Time: up to 24 weeks

No related HPO nodes (Using clinical trials)